Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Bridging The Gap With Liquid Biopsies: How It Brings Precision Medicine Closer To Reality
Friday June 19 2020 | 4:00pm - 5:00pm BST (UTC+1)
Presented by Qing Kang-Fortner, Associate Director, Syros Pharmaceuticals
- Cancer liquid biopsies based on circulating tumor DNA (ctDNA)
- The roles of ctDNA from early clinical development to real-world patient care
- Successful examples of moving ctDNA-based liquid biopsies into the clinic
Qing Kang-Fortner, Ph.D. is the Associate Director in Translational Medicine at Syros Pharmaceuticals, Inc., where she leads the oncology clinical biomarker research and companion diagnostic strategies/development for the ongoing Phase 1 and Phase 2 clinical trials. Previously she held a Scientist position at Progenity, Inc., where she led the oncology and liver disease biomarker discovery and validation, with a focus of utilizing next generation sequencing to develop diagnostic tests that influence clinical decisions. Prior to joining Progenity, she was a research fellow in Dr. Muneesh Tewari’s laboratory at the University of Michigan, where she led a multidisciplinary team to study circulating tumor DNA both in blood and urine as a non-invasive approach to detect and monitor cancer patients and also served as a group member of Cancer Moonshot Blood Profiling Atlas Program. She received a B. E. in Bioengineering from China Pharmaceutical University and a Ph.D. in Molecular Biology and Genetics from Indiana University Bloomington.